Anthony G. M. Barrett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anthony G. M. Barrett has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
Andrew J. P. White
Department of Chemistry, Imperial College, Molecular Sciences Research Hub, White City Campus, 82 Wood Lane, London W12 0BZ, England
21 shared publications- Simak Ali
Imperial College, South Kensington, London, UK
12 shared publications - Panayiotis A. Procopiou
Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
11 shared publications Laki Buluwela
10 shared publicationsAlexander Bondke
Department of Chemistry, Imperial College London, London, UK
9 shared publications- Marion Barbazanges
Sorbonne Université CNRS Institut Parisien de Chimie Moléculaire Paris France
9 shared publications
Latest Publications
- Open Access
- 13 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design
Rational design of next-generation therapeutics can be facilitated by high-resolution structures of drug targets bound to small-molecule inhibitors. However, application of structure-based methods to macromolecules refractory to crystallization has been hampered by the often-limiting resolution and throughput of cryogenic electron microscopy (cryo-EM). Here, we use high-resolution cryo-EM to determine structures of the CDK-activating kinase, a master regulator of cell growth and division, in its free and nucleotide-bound states and in complex with 15 inhibitors at up to 1.8 Å resolution. Our structures provide detailed insight into inhibitor interactions and networks of water molecules in the active site of cyclin-dependent kinase 7 and provide insights into the mechanisms contributing to inhibitor selectivity, thereby providing the basis for rational design of next-generation therapeutics. These results establish a methodological framework for the use of high-resolution cryo-EM in structure-based drug design.
- 13 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Open AccessHigh-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design
Rational design of next-generation therapeutics can be facilitated by high-resolution structures of drug targets bound to small-molecule inhibitors. However, application of structure-based methods to macromolecules refractory to crystallization has been hampered by the often-limiting resolution and throughput of cryogenic electron microscopy (cryo-EM). Here, we use high-resolution cryo-EM to determine structures of the CDK-activating kinase, a master regulator of cell growth and division, in its free and nucleotide-bound states and in complex with 15 inhibitors at up to 1.8 Å resolution. Our structures provide detailed insight into inhibitor interactions and networks of water molecules in the active site of cyclin-dependent kinase 7 and provide insights into the mechanisms contributing to inhibitor selectivity, thereby providing the basis for rational design of next-generation therapeutics. These results establish a methodological framework for the use of high-resolution cryo-EM in structure-based drug design.
- Open Access
- 7 August 2023
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 62 (33) , 13253-13276
Syntheses and Characterization of Main Group, Transition Metal, Lanthanide, and Actinide Complexes of Bidentate Acylpyrazolone Ligands
The synthesis of acylpyrazolone salts and their complexes of main group elements, transition metals, lanthanides, and actinides are described and characterized inter alia by means of single-crystal X-ray crystallography, NMR, and IR spectroscopies. The complexes consist of two, three, or four acylprazolone ligands bound to the metal atom, resulting in a structurally diverse set of coordination complexes with (distorted) octahedral, pentagonal-bipyramidal, or antiprismatic arrangements. Several complexes proved to be polymeric in the solid state including heterobimetallic sodium/lanthanide coordination polymers. A selection of the polymeric compounds was analyzed via TG/DTA measurements to establish their stability. The ligands, in turn, were readily synthesized in good yields from commercially available hydrazine hydrochloride salts. These findings demonstrate that acylpyrazolone ligands can form complexes with metals of varying ionic radii, highlighted by their utility in other areas such as analytical and metal organic framework chemistry.
- 7 August 2023
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 62 (33) , 13253-13276
Open AccessSyntheses and Characterization of Main Group, Transition Metal, Lanthanide, and Actinide Complexes of Bidentate Acylpyrazolone Ligands
The synthesis of acylpyrazolone salts and their complexes of main group elements, transition metals, lanthanides, and actinides are described and characterized inter alia by means of single-crystal X-ray crystallography, NMR, and IR spectroscopies. The complexes consist of two, three, or four acylprazolone ligands bound to the metal atom, resulting in a structurally diverse set of coordination complexes with (distorted) octahedral, pentagonal-bipyramidal, or antiprismatic arrangements. Several complexes proved to be polymeric in the solid state including heterobimetallic sodium/lanthanide coordination polymers. A selection of the polymeric compounds was analyzed via TG/DTA measurements to establish their stability. The ligands, in turn, were readily synthesized in good yields from commercially available hydrazine hydrochloride salts. These findings demonstrate that acylpyrazolone ligands can form complexes with metals of varying ionic radii, highlighted by their utility in other areas such as analytical and metal organic framework chemistry.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
ADME analysis, oral bioavailability and distribution of ICEC0942.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
ADME analysis, oral bioavailability and distribution of ICEC0942.